INTRODUCTION {#s1}
============

Prostate cancer (PCa) is one of the most common types of neoplasm in the Western world. In United States, prostate cancer is the most prevalent cancer, with 217,730 new cases predicted to occur in 2010 \[[@R1]\]. The etiology of PCa is still poorly understood, but exposure to hormones, infectious agents, or dietary carcinogens may contribute to inflammation of the prostate \[[@R2], [@R3]\]. Intraprostatic inflammation may affect the tissue microenvironment, promoting genetic damage, and driving cellular proliferation, which may lead to prostate carcinogenesis \[[@R4], [@R5]\]. Prior studies have suggested that family history is the most reproducible and significant risk factor. Men with a brother or father diagnosed with PCa were twice as likely to develop this cancer as men with no relatives affected \[[@R6]\].

Ribonuclease L (RNASEL), which is considered to be a tumor-suppressor gene, plays a significant role in the pathogenesis of prostate cancer through inflammation and infection. RNASEL is on chromosome 1q24-25 and encodes Ribonuclease L, a significant enzyme of the interferon-induced antiviral 2-5A system \[[@R7]\]. Mutation of RNASEL can lead to dysfunction of Ribonuclease L in regulating single-stranded RNA cleavage, cellular viral defense, and tumor suppressor activities, such as stress-mediated apoptosis and regulation of protein synthesis \[[@R8]--[@R9]\].

Extensive epidemiological studies had been conducted to explore the association between RNASEL polymorphism and prostate cancer risk. A G-to-A transversion at nucleotide position 1385 (rs486907), which results in a glutamine instead of arginine at amino acid position 462 (R462Q), is one of the most widely investigated polymorphisms in RNASEL. Nevertheless, the association between the RNASEL R462Q polymorphism and prostate cancer risk is controversial because of conflicting case--control studies. Therefore, in this meta-analysis from all eligible studies published to date \[[@R10]--[@R32]\], we used enhance statistical power to understand the effect of this variant.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

A total of 22 articles (including 26 case--control studies) met all the inclusion criteria and were included (Figure [1](#F1){ref-type="fig"}). The genotype distribution of the control population was consistent with Hardy-Weinberg equilibrium (HWE) in 19 of the publications. Characteristics of the eligible studies are summarized in Table [1](#T1){ref-type="table"}. In general, 11,522 prostate cancer patients and 10,976 control subjects with the RNASEL Arg462Gln polymorphism were evaluated. In the ethnic subgroups, 17 case--control studies were performed with European descendants, three with Asian descendants, and four with African descendants. We checked the Minor Allele Frequency (MAF) reported for the five main worldwide populations in the 1000 Genomes Browser: East Asian, 0.2421; European, 0.3708; African, 0.0666; American, 0.2233; and South Asian, 0.3016. The MAF in our analysis was 0.3034 and 0.2900 in the case and control group, respectively (Figure [2](#F2){ref-type="fig"}). Hospital-based controls were carried out in 15 of the studies. TaqMan real-time polymerase chain reaction (PCR), the classical genotyping method, was utilized in 10 comparisons. Five studies used the GoldenGate platform or Sequenom MassARRAY platform genotyping method. Six publications had genotype frequency information for familial and sporadic prostate cancer cases.

![Flowchart illustrating the search strategy used to identify association studies for RNASEL Arg462Gln polymorphism and prostate cancer risk](oncotarget-08-75141-g001){#F1}

###### Study characteristics of RNASEL Arg462Gln (1385G\>A) polymorphism included in this meta-analysis

  First author      Year   Country   Ethnicity      Source of   Genotype method      Sample size of case   Sample size of control                                                                   
  ----------------- ------ --------- -------------- ----------- -------------------- --------------------- ------------------------ ----- ------ ------- --------- ----- ----- ----- ------ ------- -------
  Babaei            2015   Iran      Asian          HB          PCR                  20                    15                       5     40     0.313   0.421     44    32    4     80     0.250   0.551
  Alvarez-Cubero    2015   Spain     Hispanic       HB          Goldengate assay     80                    120                      37    237    0.409   0.468     61    114   41    216    0.454   0.342
  Winchester        2015   USA       Non-Hispanic   PB          Goldengate assay     352                   407                      105   864    0.357   0.445     330   372   129   831    0.379   0.157
  San Francisco     2014   Chile     Hispanic       PB          Taqman               43                    31                       9     83     0.295   0.351     28    14    4     46     0.239   0.267
  Reza              2012   Iran      Asian          HB          Taqman               64                    73                       44    181    0.445   0.014     14    4     1     19     0.158   0.364
  Sakuma            2011   USA       Caucasian      HB          Real-time PCR        43                    55                       12    110    0.359   0.366     11    21    8     40     0.463   0.723
  Beuten            2010   USA       Hispanic       HB          Goldengate assay     75                    64                       17    156    0.314   0.550     126   91    7     224    0.234   0.048
  Meyer             2010   USA       Caucasian      PB          Sequenom MassARRAY   529                   547                      159   1235   0.350   0.346     505   546   159   1210   0.357   0.551
  Martinez-Fierro   2010   Mexico    Mixed          HB          Taqman               9                     2                        0     11     0.091   0.041     8     2     1     11     0.182   0.197
  Agalliu           2010   USA       Non-Hispanic   PB          Pyrosequencing       467                   414                      84    965    0.302   0.566     572   556   109   1237   0.313   0.110
  Wang              2009   USA       Caucasian      PB          Taqman               100                   121                      27    248    0.353   0.282     88    132   33    253    0.391   0.130
  Fischer           2008   Germany   Non-Hispanic   HB          Real time PCR        51                    29                       7     87     0.247   0.331     42    24    4     70     0.229   0.816
  Robbins           2008   USA       African        HB          Sequenom MassARRAY   183                   55                       5     243    0.134   0.718     225   66    5     296    0.128   0.950
  Shea              2008   USA       African        PB          PCR                  187                   41                       2     230    0.098   0.881     362   88    2     452    0.102   0.168
  Shook             2007   USA       African        HB          Taqman               45                    13                       10    68     0.243   \<0.001   111   31    3     145    0.128   0.633
  Shook             2007   USA       Hispanic       HB          Taqman               72                    62                       16    150    0.313   0.629     136   96    7     239    0.230   0.039
  Shook             2007   USA       Non-Hispanic   HB          Taqman               187                   183                      60    430    0.352   0.162     221   225   57    503    0.337   0.981
  Cybulski          2007   Poland    Non-Hispanic   PB          PCR-RFLP             245                   376                      116   737    0.412   0.153     177   252   82    511    0.407   0.625
  Daugherty         2007   USA       Non-Hispanic   HB          TaqMan               463                   505                      148   1116   0.359   0.578     554   602   188   1344   0.364   0.235
  Daugherty         2007   USA       African        HB          TaqMan               73                    23                       2     98     0.138   0.905     277   98    5     380    0.142   0.261
  Maier             2005   Germany   Non-Hispanic   PB          PCR                  133                   171                      59    363    0.398   0.746     73    97    37    207    0.413   0.629
  Nam               2005   Canada    Mixed          PB          Mass spectrometry    477                   409                      110   996    0.316   0.117     521   459   112   1092   0.313   0.464
  Wiklund           2004   Sweden    Non-Hispanic   PB          TaqMan               597                   778                      247   1622   0.392   0.804     297   384   115   796    0.386   0.611
  Nakazato          2003   Japan     Asian          HB          PCR                  69                    32                       0     101    0.158   0.059     71    26    8     105    0.200   0.020
  Rokman            2002   Finland   Non-Hispanic   HB          PCR                  88                    106                      39    233    0.395   0.464     69    84    23    176    0.369   0.745
  Wang              2002   USA       Caucasian      PB          PCR                  389                   427                      102   918    0.344   0.347     193   233   67    493    0.372   0.802

HWE: Hardy-Weinberg equilibrium of controls, HB: Hospital-based; PB: Population-based; MAF: Minor Allele Frequency.

![A-allele frequencies for the RNASEL Arg462Gln polymorphism in the controls stratified by ethnicity\
Vertical line, A-allele frequency; Horizontal line, ethnicity type.](oncotarget-08-75141-g002){#F2}

Quantitative synthesis {#s2_2}
----------------------

When all the eligible studies were pooled into the analysis (Table [2](#T2){ref-type="table"}), no positive association was observed for allelic contrast (fixed-effects OR = 0.99, 95% CI = 0.95 - 1.03, *P*~heterogeneity~ = 0.004, *P* = 0.758, *I*^2^ = 47.9), homozygote comparison (fixed-effects OR = 1.00, 95% CI = 0.91 - 1.09, *P*~heterogeneity~ = 0.001, *P* = 0.968, *I*^2^ = 54.2), heterozygote comparison (fixed-effects OR = 1.01, 95% CI = 0.92 - 1.10, *P*~heterogeneity~ = 0.029, *P* = 0.861, *I*^2^ = 37.6), the dominant genetic model (fixed-effects OR = 0.99, 95% CI = 0.93 - 1.04, *P*~heterogeneity~ = 0.361, *P* = 0.653, *I*^2^ = 7.0), and the recessive genetic model(fixed-effects OR = 1.00, 95% CI = 0.92 -- 1.09, *P*~heterogeneity~ = 0.002, *P* = 0.960, *I*^2^ = 50.3). However, in the subgroup analysis by ethnicity, obvious associations between the RNASEL Arg462Gln polymorphism and prostate cancer risk were observed in African descendants for homozygote comparison (fixed-effects OR = 2.59, 95% CI = 1.29 -- 5.19, *P*~heterogeneity~ = 0.194, *P* = 0.008, *I*^2^ = 36.3), and the recessive genetic model (fixed-effects OR = 2.61, 95% CI = 1.30 -- 5.23, *P*~heterogeneity~ = 0.195, *P* = 0.007, *I*^2^ = 36.1); and for Hispanic Caucasians for the recessive genetic model (fixed-effects OR = 1.44, 95% CI = 1.01 - 2.05, *P*~heterogeneity~ = 0.002, *P* = 0.046, *I*^2^ = 79.9), homozygote comparison (fixed-effects OR = 1.50, 95% CI = 1.02 -- 2.20, *P*~heterogeneity~ = 0.001, *P* = 0.039, *I*^2^ = 82.3), and allelic contrast (fixed-effects OR = 1.18, 95% CI = 1.00 - 1.39, *P*~heterogeneity~ = 0.010, *P* = 0.050, *I*^2^ = 73.5). No association was observed in Asian descendants for allelic contrast (fixed-effects OR = 1.30, 95% CI = 0.93 -- 1.83, *P*~heterogeneity~ = 0.004, *P* = 0.126, *I*^2^ = 82.2), homozygote comparison (fixed-effects OR = 1.49, 95% CI = 0.70 -- 3.17, *P*~heterogeneity~ = 0.013, *P* = 0.303, *I*^2^ = 76.9), and the recessive genetic model (fixed-effects OR = 1.23, 95% CI = 0.57 -- 2.63, *P*~heterogeneity~ = 0.019, *P* = 0.600, *I*^2^ = 74.8); non-Hispanic Caucasians for allelic contrast (fixed-effects OR = 0.99, 95% CI = 0.94 -- 1.04, *P*~heterogeneity~ = 0.856, *P* = 0.641, *I*^2^ = 0) homozygote comparison (fixed-effects OR = 0.98, 95% CI = 0.87 -- 1.10, *P*~heterogeneity~ = 0.631, *P* = 0.701, *I*^2^ = 0), and the recessive genetic model (fixed-effects OR = 0.98, 95% CI = 0.88 -- 1.09, *P*~heterogeneity~ = 0.487, *P* = 0.680, *I*^2^ = 0); and mixed descendants for allelic contrast (fixed-effects OR = 1.01, 95% CI = 0.89 -- 1.15, *P*~heterogeneity~ = 0.381, *P* = 0.886, *I*^2^ = 0), homozygote comparison (fixed-effects OR = 1.06, 95% CI = 0.79 -- 1.42, *P*~heterogeneity~ = 0.453, *P* = 0.692, *I*^2^ = 0), and the recessive genetic model (fixed-effects OR = 1.07, 95% CI = 0.81 -- 1.42, *P*~heterogeneity~ = 0.452, *P* = 0.610, *I*^2^ = 0) (Figure [3](#F3){ref-type="fig"}). Furthermore, a significant association was also observed under the recessive genetic model (random-effects OR = 1.45, 95% CI = 1.01 -- 2.08, *P*~heterogeneity~ \< 0.001, *P* = 0.046, *I*^2^ = 64.8) between the RNASEL polymorphism and hospital-based controls (Figure [4](#F4){ref-type="fig"}). Interestingly, in a stratified analysis by the type of prostate cancer, a positive association was observed in familial prostate cancer for allelic contrast (fixed-effects OR = 0.89, 95% CI = 0.79 -- 0.99, *P*~heterogeneity~ = 0.209, *P* = 0.028, *I*^2^ = 31.8) and homozygote comparison (fixed-effects OR = 0.77, 95% CI = 0.61 -- 0.98, *P*~heterogeneity~ = 0.136, *P* = 0.037, *I*^2^ = 42.9), but not in sporadic prostate cancer for allelic contrast (fixed-effects OR = 1.02, 95% CI = 0.94 -- 1.10, *P*~heterogeneity~ = 0.774, *P* = 0.671, *I*^2^ = 0) and homozygote comparison (fixed-effects OR = 1.06, 95% CI = 0.89 -- 1.27, *P*~heterogeneity~ = 0.640, *P* = 0.503, *I*^2^ = 0).

###### Stratified analyses of the RNASEL Arg462Gln polymorphism on prostate cancer risk

  Variables                 N^a^   Cases/        A-allele vs. G-allele   AA vs. GG   AA vs. GA+GG                                                                                             
  ------------------------- ------ ------------- ----------------------- ----------- -------------- ------ ---------------- ------- ------------ ------ ---------------- ------- ------------ ------
  Total                     26     11522/10976   0.99(0.95-1.03          0.758       0.004          47.9   1.00(0.91-1.09   0.968   0.001        54.2   1.00(0.92-1.09   0.960   0.002        50.3
  Ethnicity                                                                                                                                                                                   
  Asian                     3      322/204       1.30(0.93-1.83          0.126       0.004          82.2   1.49(0.70-3.17   0.303   0.013        76.9   1.23(0.57-2.63   0.600   0.019        74.8
  African                   4      639/1273      1.12(0.91-1.37          0.281       0.056          60.3   2.59(1.29-5.19   0.008   0.194        36.3   2.61(1.30-5.23   0.007   0.195        36.1
  Caucasian                 4      2511/1996     0.92(0.84-1.00          0.058       0.371          4.4    0.84(0.70-1.02   0.081   0.319        14.6   0.88(0.74-1.06   0.173   0.462        0
  Hispanic Caucasians       4      626/725       1.18(1.00-1.35          0.050       0.010          73.5   1.50(1.02-2.20   0.039   0.001        82.3   1.44(1.01-2.05   0.046   0.002        79.9
  Non-Hispanic Caucasians   9      6417/5675     0.99(0.94-1.04          0.641       0.856          0      0.98(0.87-1.10   0.701   0.631        0      0.98(0.88-1.09   0.680   0.487        0
  Mixed                     2      1007/1103     1.01(0.89-1.15          0.886       0.381          0      1.06(0.79-1.42   0.692   0.453        0      1.07(0.81-1.42   0.610   0.452        0
  Source of control                                                                                                                                                                           
  Hospital-based            15     3261/3848     1.06(0.98-1.14          0.120       0.001          63.1   1.47(0.99-2.20   0.059   \<0.001^c^   67.9   1.45(1.01-2.08   0.046   \<0.001^c^   64.8
  Population-based          11     8261/7128     0.97(0.92-1.01          0.169       0.802          0      0.94(0.84-1.04   0.235   0.709        0      0.95(0.86-1.05   0.296   0.739        0
  Type of prostate cancer                                                                                                                                                                     
  Sporadic Pca              6      2838/2934     1.02(0.94-1.10          0.671       0.774          0      1.06(0.89-1.27   0.503   0.640        0      1.07(0.91-1.26   0.441   0.679        0
  Familial Pca              5      1313/1967     0.89(0.79-0.99          0.028       0.209          31.8   0.77(0.61-0.98   0.037   0.145        31.8   0.81(0.65-1.02   0.070   0.210        31.7

^a^ Number of comparisons

^b^ *P* value of *Q*-test for heterogeneity test(*P*~heter~).

^c^ Random effects model was performed when *P*~heter~ \<0.001; otherwise, fixed effects model was used.

![Forest plot of prostate cancer risk associated with RNASEL Arg462Gln polymorphism (recessive genetic model) in the stratified analysis by ethnicity\
The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI. Separate details were summarized in Table [1](#T1){ref-type="table"}.](oncotarget-08-75141-g003){#F3}

![Forest plot of prostate cancer risk associated with RNASEL Arg462Gln polymorphism (recessive genetic model of AA vs. GA + GG) by source of control\
The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](oncotarget-08-75141-g004){#F4}

Publication bias {#s2_3}
----------------

The Egger's test and Begg's funnel plot were carried out to assess the publication bias of the literature. No obvious evidence of publication bias was found (A-allele vs. G-allele, t = 1.72, *P* = 0.098; AA vs. GG, t = 1.77, *P* = 0.089; GA vs. GG, t = 1.75, *P* = 0.094; AA + GA vs. AA, t = 1.23, *P* = 0.231; AA vs. GA + GG, t = 1.77, *P* = 0.090)

DISCUSSION {#s3}
==========

Published studies have shown evidence that RNASEL is a constitutively expressed latent endo-ribonuclease that mediates proapoptotic and antiviral activities of the IFN-inducible 2-5A system \[[@R7]--[@R9]\]. Mutation carriers in the RNASEL gene have loss of heterozygosity and are deficient in functional RNase L activity \[[@R33]\]. However, previous reports showing association between RNASEL polymorphism and prostate cancer susceptibility are contradictory. The general goal of this pooled analysis is to quantitatively analyze previous studies to understand the true relationship between RNASEL polymorphism and prostate cancer. Here, previous case-control studies with information between the RNASEL polymorphism and different types of Caucasians (Hispanic and Non-Hispanic) were included. As a result, some new findings were observed in our meta-analysis.

Our results indicated that the RNASEL Arg462Gln polymorphism may be associated with increased prostate cancer in African descendants (under homozygote comparison and the recessive genetic model) and Hispanic Caucasians (under allelic contrast, homozygote comparison, and the recessive genetic model), but not in Asian descendants and Non-Hispanic Caucasians. Furthermore, in a stratified analysis by source of control, the RNASEL Arg462Gln variant was found to increase prostate cancer risk in hospital-based studies (under the recessive genetic model). Nevertheless, several caveats limit generalization of these results. First, detailed information, such as age, prognostic parameters, environmental factors, and life-style, were not considered. Second, because different types of prostate cancer influence susceptibility, we tried to assess the effect of this polymorphism to different types of prostate cancer but not all data was compatible. Third, positive findings may be published faster than that those with "negative" results, which may result in a time-lag bias \[[@R34]\]. In addition, more environmental interactions, such as smoking habits, dietary factors, hormone exposure, toxins, and infectious agent, need to be added to the meta-analysis in the future.

Other limitations of the meta-analysis need to be addressed. First, while it is possible that the Arg462Gln polymorphism contributes to cancer, the combined effects of multiple environmental or genetic components predominate in the development of carcinoma, and may mask the effect of the polymorphism \[[@R35]\]. Second, the present analysis was based on unadjusted estimates. A more precise analysis with individual data is needed to evaluate combinatorial effects of the polymorphism \[[@R36]\]. Despite these concerns, the current analysis has some advantages compared with the individual studies. First, a substantial number of cases and controls were pooled from different studies, which significantly enhance the statistical power of this analysis. Second, the quality of case-control studies enrolled in our analysis was satisfactory based on the selection criteria. Third, no obvious publication bias was observed, which indicates that the conclusions were relatively stable and the publication bias might not influence the conclusions of the present meta-analysis.

In conclusion, this meta-analysis showed evidence that the RNASEL Arg462Gln polymorphism may contribute to the risk for developing prostate cancer in African descendants and Hispanic Caucasians, but not for other descendants. Further well-designed and prospective studies, particularly focused on gene-environment interactions, are warranted. These future studies should lead to a comprehensive understanding of the association between the RNASEL Arg462Gln polymorphism and prostate cancer risk.

MATERIALS AND METHODS {#s4}
=====================

Search strategy and identification of relevant studies {#s4_1}
------------------------------------------------------

PubMed database searches were conducted using the following keywords: "ribonuclease L" or "RNASEL", "prostate cancer", and "polymorphism" (last search updated on March 01, 2017). References of the relevant articles and retrieved paper were also screened by hand search. Eligible studies had to meet all the following criteria: (a) used an unrelated case--control design; (b) contained information about available genotype frequency; (c) published in English; and (d) included the full-text article.

Data extraction and quality assessment {#s4_2}
--------------------------------------

Data were collected on the genotype of rs486907 G/A (R462Q) according to prostate cancer. For each publication, the data extraction and methodological quality assessment were conducted by two of the investigators independently to ensure accuracy of the data. Disagreement was resolved by discussion between the two investigators. If they could not reach a consensus, the problem was discussed by all investigators to reach a consensus. The following parameters from each study were recorded: first author's name, publication date, ethnicity, sources of cancer cases and controls, sample size in cases and controls, and the number of cases and controls with wild-type and variant allele, respectively.

Statistical analysis {#s4_3}
--------------------

Crude ORs with 95% CIs were utilized to evaluate the strength of association between the RNASEL polymorphism and prostate cancer based on genotype frequencies in cases and controls. Five genetic contrasts were used to assess the association: allelic contrast (A-allele vs. G-allele), homozygote comparison (AA vs. GG), heterozygote comparison (GA vs. GG), the dominant genetic model (AA + GA vs. GG), and the recessive genetic model (AA vs. GA + GG). Subgroup analysis was stratified by ethnicity, source of control (hospital-based and population-based), and smoking exposure. We utilized the random effects model and fixed effects model to calculate the pooled OR. Heterogeneity assumption was evaluated by a chi-square-based *Q* test. *P* value lower than 0.001 for the *Q*-test indicates lack of heterogeneity among studies, hence the pooled OR was utilized by the random effects model (DerSimoniane and Laird method \[[@R37]\] or by the fixed-effects model (the Mantel-Haenszel method \[[@R38]\]). HWE was checked by the Pearson chi-square test for goodness of fit. A *Z*-test was used to evaluate statistical significance of the summary OR, and *P* value of ≤ 0.05 was considered significant. We also utilized the *I*^2^ statistic to test heterogeneity, with *I*^2^ \>75%, 25--75%, and \< 25% to represent high, moderate, and low degree of inconsistency, respectively \[[@R39]\]. We determined significance of the intercept by t-test suggested by Egger (*P* \< 0.01 was considered representative of significant publication bias) \[[@R40]\]. All statistical analyses were performed with STATA version 11.0 (Stata Corporation, College Station, TX), utilizing two-sided *P* values.
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